Variant lambda of the severe acute respiratory syndrome coronavirus 2: A serious threat or the beginning of further dangerous mutations.

Szarpak, Lukasz; Savytskyi, Ivan; Pruc, Michal; Gozhenko, Anatolyi; Filipiak, Krzysztof J; Rafique, Zubaid; Peacock, Frank W; Ilesanmi, Olayinka S; Chirico, Francesco

Szarpak, Lukasz; Savytskyi, Ivan; Pruc, Michal; Gozhenko, Anatolyi; Filipiak, Krzysztof J; Rafique, Zubaid; Peacock, Frank W; Ilesanmi, Olayinka S; Chirico, Francesco.

Szarpak L; Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland. lukasz.szarpak@gmail.com.
Savytskyi I; Research Unit, Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland. lukasz.szarpak@gmail.com.
Pruc M; Polish Society of Disaster Medicine, Warsaw, Poland. lukasz.szarpak@gmail.com.
Gozhenko A; International European University, Kiev, Ukraine.
Filipiak KJ; Polish Society of Disaster Medicine, Warsaw, Poland.
Rafique Z; Institute of Outcomes Research, Polonia University, Warsaw, Poland.
Peacock FW; International European University, Kiev, Ukraine.
Ilesanmi OS; Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland.
Chirico F; Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, United States.

Cardiol J ; 29(1): 176-177, 2022.

Article in English | MEDLINE | ID: covidwho-1468675

Subject(s)

COVID-19; SARS-CoV-2; Humans; Mutation

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Topics: Variants Limits: Humans Language: English Journal: Cardiol J Year: 2022 Document Type: Article Affiliation country: CJ.a2021.0121

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google